Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
SCI-att is the radiopharmaceutical tools and precursor subsidiary of Scintomics, supplying GMP and R&D precursors (e.g., PSMA I&T, SiFAlin-TATE, next‑generation PSMA inhibitors) and operating the GRP radiosynthesis platform used in routine clinical production of PET/SPECT tracers worldwide; its technologies underpin clinically developed radiohybrid PSMA and CXCR4 theranostic tracers that have reached late-stage clinical development and regulatory approval via licensees such as Blue Earth Diagnostics and others.[1][2][4][7][9][10]
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on SCINTOMICS Molecular, Applied Theranostics Technologies.